A recent study by Monti et al. (2022) analysed The Cancer Genome Atlas dataset and found that ERK5 expression was variable across tumour type, but patients with high ERK5 expression were associated with worse overall survival time. This evidence concerns the gene MAPK7 and neoplasm.